- Home
- FC vs PBYI Comparison
FC vs PBYI Comparison
Compare FC & PBYI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FC | PBYI |
|---|---|---|
| Founded | 1983 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 157.5M | 263.4M |
| IPO Year | 1994 | 2011 |
Fundamental Metrics
Financial Performance| Metric | FC | PBYI |
|---|---|---|
| Price | $11.64 | $6.00 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $26.00 | N/A |
| AVG Volume (30 Days) | 161.3K | ★ 429.2K |
| Earning Date | 04-01-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 0.61 |
| Revenue | ★ $267,067,000.00 | $27,685,000.00 |
| Revenue This Year | $3.02 | N/A |
| Revenue Next Year | $3.66 | N/A |
| P/E Ratio | ★ N/A | $9.84 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $11.16 | $2.58 |
| 52 Week High | $29.52 | $7.68 |
Technical Indicators
Market Signals| Indicator | FC | PBYI |
|---|---|---|
| Relative Strength Index (RSI) | 22.09 | 42.49 |
| Support Level | N/A | $5.57 |
| Resistance Level | $20.19 | $6.15 |
| Average True Range (ATR) | 0.57 | 0.37 |
| MACD | 0.10 | -0.05 |
| Stochastic Oscillator | 23.62 | 33.18 |
Price Performance
Historical ComparisonAbout FC Franklin Covey Company
Franklin Covey Co is a company focused on organizational performance improvement. It operates in the business segments of North America, International Direct Offices, International Licensees, Education Division. The company derives revenue from providing training and consulting services and through the sale of books, audio media, and other related products. It has a business presence in Australia, New Zealand, China, Japan, the United Kingdom, Ireland, and Other countries.
About PBYI Puma Biotechnology Inc
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis resulting into apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.